Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01604889 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01604889 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 50 participants.
The verdict
NCT01604889, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The study design included an open-label, dose escalation phase followed by a blinded, randomized phase, which combined epacadostat (an oral IDO1 inhibitor) with an approved therapy and compared to approved therapy plus placebo in metastatic melanoma patients. Only Phase 1 of the study, dose escalation phase, was conducted. The study was terminated due to a business decision.
Interventions
- DRUG Epacadostat
- DRUG ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-03-29 |
| Est. Completion | 2017-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01604889
The ClinicalTrials.gov registry entry for NCT01604889 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epacadostat is the first listed.
NCT01604889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01604889 about?
NCT01604889 is a clinical study titled "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma". The study design included an open-label, dose escalation phase followed by a blinded, randomized phase, which combined epacadostat (an oral IDO1 inhibitor) with an approved therapy and compared to approved therapy plus placebo in metastatic melanoma patients. Only Phase 1 of the study, dose escalat...
What is the current status of trial NCT01604889?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2012-03-29. Estimated completion is 2017-01-20.
What interventions are being tested in trial NCT01604889?
The interventions under investigation include: Epacadostat (DRUG), ipilimumab (DRUG).
Who is sponsoring clinical trial NCT01604889?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.